Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients.

Abstract

Bevacizumab treatment is associated with an increased risk of hypertension (HTN), a potential marker for effectiveness. We aimed to assess whether grades 2-3 HTN during bevacizumab treatment was associated with increased overall survival (OS) or progression-free survival (PFS). One hundred and eighty-one patients with metastatic colorectal cancer (CRC), who were treated in our Department from January 2009-February 2011 were included. Bevacizumab was administered jointly with standard first- or second-line chemotherapy protocols. Blood pressure was measured before each treatment. HTN was graded using common toxicity criteria. There were 181 CRC patients. Grades 2-3 HTN developed in 81 patients (44.75 %) but not in 100 patients (55.25 %); no patient developed grades 4-5 HTN. Median follow-up was 15.2 months. HTN was associated with better OS in HTN-positive versus HTN-negative patients (median not reached vs. 36.8 months, p = 0.029) and better PFS (29.9 vs. 17.2 months, p = 0.024, respectively). Bevacizumab-related HTN may represent a biomarker for clinical benefit in metastatic colorectal cancer patients.

• Authors: Esther Tahover, Beatrice Uziely, Azzam Salah, Mark Temper, Tamar Peretz, Ayala Hubert
• Journal: Medical oncology (Northwood, London, England) (Med Oncol) Vol. 30 Issue 1 Pg. 327 (Mar 2013) ISSN: 1559-131X [Electronic] United States
• PMID: 23254964 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Adult
• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Colorectal Neoplasms (drug therapy, mortality)
• Disease-Free Survival
• Female
• Humans
• Hypertension (chemically induced)
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Retrospective Studies
• Treatment Outcome